* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
{(S)-1-[(S)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid ethyl ester[ No CAS ]
{(S)-1-[(S)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-pentylcarbamoyl)-2-(1H-imidazol-4-yl)-ethylcarbamoyl]-2-phenyl-ethyl}-carbamic acid ethyl ester[ No CAS ]
General procedure: All protected amino acids were coupled in CH2Cl2 (5 ml) using DCC (2.5 equiv.) and HOBt (2.5 equiv.) until completion (3 h) judged by Kaiser [15] ninhydrin test. After coupling of the appropriate amino acid, Boc deprotection was effected by use of TFA/CH2Cl2 (1:1, 5 ml)) for 5 min first then repeated for 25 min. Following neutralization with 10% TEA/CH2Cl2 three times (5-5 ml of each), the synthetic cycle was repeated to assemble the resin-bond protected peptide. The peptides were cleaved from the resin with simultaneous side chain deprotection by acidolysis with anhydrous hydrogen fluoride (5 ml) containing 2% anisole, 8% dimethyl sulfide and indole at 5 C for 45 min. The crude peptides were dissolved in aqueous acetic acid and lyophilized.
Chemistry
Pharmaceutical Intermediates
Inhibitors/Agonists
Material Science
For Research Only
120K+ Compounds
Competitive Price
1-2 Day Shipping
